Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

NCT05427370 · View on ClinicalTrials.gov ↗

Study Summary

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH3C) trial is a prospective, unblinded, international multi-center randomized trial of 754 subjects enrolled in approximately 45 centers comparing revascularization by percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with multivessel/left main (LM) coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF). The primary objective is to determine whether CABG compared to PCI is associated with a reduction in all-cause death, stroke, spontaneous myocardial infarction (MI), urgent repeat revascularization (RR), or heart failure (HF) readmission over a median follow-up of 5 years in patients with multivessel/LM CAD and ischemic left ventricular dysfunction (iLVSD). Eligible patients are considered by the local Heart Team appropriate and amenable for non-emergent revascularization by both modes of revascularization. The secondary objectives are to describe the early risks of both procedures, and a comprehensive set of patient-reported outcomes longitudinally.

Interventions

  • PROCEDURE Revascularization by PCI
  • PROCEDURE Revascularization by CABG

Study Locations (20)

Ontario

  • Hamilton General Hospital — Hamilton
  • London Health Sciences Center, University Hospital — London
  • Southlake Regional HC — Newmarket
  • Ottawa Heart Institute — Ottawa
  • Sunnybrook Health Sciences Center — Toronto
  • St. Michael's — Toronto
  • Toronto General Hospital — Toronto

Other

  • Medical University of Vienna — Vienna
  • Heart Institute, Medical School of the University of Sao Paulo_INCOR — São Paulo

Alberta

  • University of Calgary; Libin Cardiovascular Institute — Calgary
  • Mackenzie Health Sciences Center — Edmonton

British Columbia

  • Fraser Health; Royal Columbian Hospital — New Westminster
  • Providence Health — Vancouver

California

  • Cedars-Sinai — Los Angeles

Connecticut

  • Yale University — New Haven

Kentucky

  • UofL Health, Inc — Louisville

Maryland

  • John Hopkins Hospital — Baltimore

Trial Details

FieldValue
Enrollment Target 754 participants
Start Date 2023-06-22
Est. Completion 2029-12
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05427370

The ClinicalTrials.gov registry entry for NCT05427370 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 754 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sunnybrook Health Sciences Centre, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions — of which Revascularization by PCI is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05427370 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Ontario, Other, Alberta. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05427370 about?

NCT05427370 is a clinical study titled "The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)". The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH3C) trial is a prospective, unblinded, international multi-center randomized trial of 754 subjects enrolled in approximately 45 centers comparing revascularization by percutaneous coronary intervention (PCI) vs. coronary artery ...

What is the current status of trial NCT05427370?

This trial is currently recruiting. It is a NA study. The enrollment target is 754 participants. The study started on 2023-06-22. Estimated completion is 2029-12.

What conditions does trial NCT05427370 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Heart Failure Systolic. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05427370?

The interventions under investigation include: Revascularization by PCI (PROCEDURE), Revascularization by CABG (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05427370?

This trial is sponsored by Sunnybrook Health Sciences Centre, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05427370 being conducted?

This trial has 20 study locations across California, Connecticut, Kentucky, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial